1
|
Hofman P, Calabrese F, Kern I, Adam J, Alarcão A, Alborelli I, Anton NT, Arndt A, Avdalyan A, Barberis M, Bégueret H, Bisig B, Blons H, Boström P, Brcic L, Bubanovic G, Buisson A, Caliò A, Cannone M, Carvalho L, Caumont C, Cayre A, Chalabreysse L, Chenard MP, Conde E, Copin MC, Côté JF, D'Haene N, Dai HY, de Leval L, Delongova P, Denčić-Fekete M, Fabre A, Ferenc F, Forest F, de Fraipont F, Garcia-Martos M, Gauchotte G, Geraghty R, Guerin E, Guerrero D, Hernandez S, Hurník P, Jean-Jacques B, Kashofer K, Kazdal D, Lantuejoul S, Leonce C, Lupo A, Malapelle U, Matej R, Merlin JL, Mertz KD, Morel A, Mutka A, Normanno N, Ovidiu P, Panizo A, Papotti MG, Parobkova E, Pasello G, Pauwels P, Pelosi G, Penault-Llorca F, Picot T, Piton N, Pittaro A, Planchard G, Poté N, Radonic T, Rapa I, Rappa A, Roma C, Rot M, Sabourin JC, Salmon I, Prince SS, Scarpa A, Schuuring E, Serre I, Siozopoulou V, Sizaret D, Smojver-Ježek S, Solassol J, Steinestel K, Stojšić J, Syrykh C, Timofeev S, Troncone G, Uguen A, Valmary-Degano S, Vigier A, Volante M, Wahl SGF, Stenzinger A, Ilié M. Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe. ESMO Open 2023; 8:101628. [PMID: 37713929 PMCID: PMC10594022 DOI: 10.1016/j.esmoop.2023.101628] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2023] [Revised: 06/14/2023] [Accepted: 08/02/2023] [Indexed: 09/17/2023] Open
Abstract
BACKGROUND Testing for epidermal growth factor receptor (EGFR) mutations is an essential recommendation in guidelines for metastatic non-squamous non-small-cell lung cancer, and is considered mandatory in European countries. However, in practice, challenges are often faced when carrying out routine biomarker testing, including access to testing, inadequate tissue samples and long turnaround times (TATs). MATERIALS AND METHODS To evaluate the real-world EGFR testing practices of European pathology laboratories, an online survey was set up and validated by the Pulmonary Pathology Working Group of the European Society of Pathology and distributed to 64 expert testing laboratories. The retrospective survey focussed on laboratory organisation and daily EGFR testing practice of pathologists and molecular biologists between 2018 and 2021. RESULTS TATs varied greatly both between and within countries. These discrepancies may be partly due to reflex testing practices, as 20.8% of laboratories carried out EGFR testing only at the request of the clinician. Many laboratories across Europe still favour single-test sequencing as a primary method of EGFR mutation identification; 32.7% indicated that they only used targeted techniques and 45.1% used single-gene testing followed by next-generation sequencing (NGS), depending on the case. Reported testing rates were consistent over time with no significant decrease in the number of EGFR tests carried out in 2020, despite the increased pressure faced by testing facilities during the COVID-19 pandemic. ISO 15189 accreditation was reported by 42.0% of molecular biology laboratories for single-test sequencing, and by 42.3% for NGS. 92.5% of laboratories indicated they regularly participate in an external quality assessment scheme. CONCLUSIONS These results highlight the strong heterogeneity of EGFR testing that still occurs within thoracic pathology and molecular biology laboratories across Europe. Even among expert testing facilities there is variability in testing capabilities, TAT, reflex testing practice and laboratory accreditation, stressing the need to harmonise reimbursement technologies and decision-making algorithms in Europe.
Collapse
Affiliation(s)
- P Hofman
- Laboratory of Clinical and Experimental Pathology, FHU OncoAge, Biobank Côte d'Azur BB-0033-00025, Louis Pasteur Hospital, IRCAN, Université Côte d'Azur, Nice, France.
| | - F Calabrese
- Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy
| | - I Kern
- Department of Pathology, University Clinic Golnik, Golnik, Slovenia
| | - J Adam
- Department of Pathology, Groupe Hospitalier Paris Saint-Joseph, Paris, France
| | - A Alarcão
- IAP-PM, Institute of Anatomical and Molecular Pathology, Faculty of Medicine, University of Coimbra, 3004-504 Coimbra, Portugal
| | - I Alborelli
- Department of Pathology, Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland
| | - N T Anton
- Department of Genetics, University Hospital Bichat-Claude Bernard, Paris University, Paris, France
| | - A Arndt
- Institute of Pathology and Molecular Pathology, Bundeswehrkrankenhaus Ulm, Oberer Eselsberg 40, 89081 Ulm, Germany
| | - A Avdalyan
- Multidisciplinary Clinical Center "Kommunarka" of the Moscow Health Department, Moscow, Russia
| | - M Barberis
- Oncogenomics Unit, European Institute of Oncology (IEO), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy
| | - H Bégueret
- Department of Pathology, University Hospital of Bordeaux, Hôpital Haut-Lévêque, Pessac, France
| | - B Bisig
- Institute of Pathology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| | - H Blons
- Pharmacogenomics and Molecular Oncology Unit, Biochemistry Department, Assistance Publique-Hopitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France
| | - P Boström
- Department of Pathology, Turku University Hospital, Turku, Finland
| | - L Brcic
- Diagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria
| | - G Bubanovic
- Laboratory for Molecular Pathology, Department of Pathology, University of Zagreb School of Medicine and University Hospital Centre Zagreb, Zagreb, Croatia
| | - A Buisson
- Department of Biopathology, Centre Léon Bérard, Lyon, France
| | - A Caliò
- Department of Diagnostics and Public Health, Section of Pathology, University and Hospital Trust of Verona, Verona, Italy
| | - M Cannone
- Inter-Hospital Pathology Division, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), MultiMedica, Milan, Italy
| | - L Carvalho
- IAP-PM, Institute of Anatomical and Molecular Pathology, Faculty of Medicine, University of Coimbra, 3004-504 Coimbra, Portugal
| | - C Caumont
- Department of Tumor Biology, University Hospital of Bordeaux, Hospital Haut-Lévêque, Pessac, France
| | - A Cayre
- Department of Biopathology, Jean Perrin Centre, Clermont-Ferrand, France
| | - L Chalabreysse
- Department of Pathology, Groupement Hospitalier Est, Bron, France
| | - M P Chenard
- Department of Pathology, University Hospital of Strasbourg, 67098 Strasbourg, France
| | - E Conde
- Department of Pathology, 12 de Octubre University Hospital, Universidad Complutense de Madrid, Research Institute 12 de Octubre University Hospital (i+12), CIBERONC, Madrid, Spain
| | - M C Copin
- Department of Pathology, Université d'Angers, Centre Hospitalier Universitaire d'Angers, Angers, France
| | - J F Côté
- Department of Pathology, Institut Mutualiste Montsouris, Paris, France
| | - N D'Haene
- Department of Pathology, Erasme Hospital, HUB ULB, Brussels, Belgium
| | - H Y Dai
- Department of Pathology, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway
| | - L de Leval
- Institute of Pathology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| | - P Delongova
- Institute of Molecular and Clinical Pathology and Medical Genetics, Faculty of Medicine, University Hospital Ostrava, Ostrava, Czech Republic
| | | | - A Fabre
- Department of Histopathology, St. Vincent's University Hospital, University College Dublin School of Medicine, Dublin, Ireland
| | - F Ferenc
- Department of Pathology, University of Oradea, Oradea, Romania
| | - F Forest
- Department of Pathology, University Hospital of Saint-Etienne, Saint-Etienne, France
| | - F de Fraipont
- Medical Unit of Molecular Genetic (Hereditary Diseases and Oncology), Grenoble University Hospital, Grenoble, France
| | - M Garcia-Martos
- Department of Pathology, Gregorio Marañón General University Hospital, Madrid, Spain
| | - G Gauchotte
- Department of Biopathology, CHRU-ICL, CHRU Nancy, Vandoeuvre-lès-Nancy, France
| | - R Geraghty
- Department of Histopathology, St. Vincent's University Hospital, University College Dublin School of Medicine, Dublin, Ireland
| | - E Guerin
- Department of Molecular Cancer Genetics, Laboratory of Biochemistry and Molecular Biology, University Hospital of Strasbourg, Strasbourg, France
| | - D Guerrero
- Biomedical Research Centre, Navarra Health Service, Pamplona, Navarra, Spain
| | - S Hernandez
- Department of Pathology, 12 de Octubre University Hospital, Universidad Complutense de Madrid, Research Institute 12 de Octubre University Hospital (i+12), CIBERONC, Madrid, Spain
| | - P Hurník
- Institute of Molecular and Clinical Pathology and Medical Genetics, Faculty of Medicine, University Hospital Ostrava, Ostrava, Czech Republic
| | - B Jean-Jacques
- Department of Pathology, CHU de Caen Côte de Nacre, Caen, France
| | - K Kashofer
- Diagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria
| | - D Kazdal
- Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany; Translational Lung Research Center Heidelberg (TLRC-H), member of the German Center for Lung Research (DZL), Heidelberg, Germany
| | - S Lantuejoul
- Department of Biopathology, Centre Leon Berard Unicancer and Pathology Research Platform, Cancer Research Center of Lyon (CRCL), Lyon, France
| | - C Leonce
- Department of Pathology, Groupement Hospitalier Est, Bron, France
| | - A Lupo
- Department of Pathology, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Université de Paris, Paris, France
| | - U Malapelle
- Department of Public Health, University of Naples Federico II, Naples, Italy
| | - R Matej
- Department of Pathology and Molecular Medicine, Thomayer University Hospital, Prague, Czech Republic
| | - J L Merlin
- Department of Biopathology, Institut de Cancérologie de Lorraine, University of Lorraine, Vandoeuvre-Les-Nancy, France
| | - K D Mertz
- Institute of Pathology, Cantonal Hospital Baselland, Liestal, Switzerland
| | - A Morel
- Department of Innate Immunity and Immunotherapy, Institut de Cancérologie de l'Ouest - Centre Paul Papin, Angers, France
| | - A Mutka
- HUSLAB, Department of Pathology, Helsinki University Hospital, Helsinki, Finland
| | - N Normanno
- Cell Biology and Biotherapy Unit, INT-Fondazione Pascale, Via M. Semmola, Naples, Italy
| | - P Ovidiu
- Department of Pathology, University of Oradea, Oradea, Romania
| | - A Panizo
- Department of Pathology, Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain
| | - M G Papotti
- Division of Pathology, University Hospital Città Della Salute, Turin, Italy
| | - E Parobkova
- Department of Pathology and Molecular Medicine, Thomayer University Hospital, Prague, Czech Republic
| | - G Pasello
- Division of Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy
| | - P Pauwels
- Department of Pathology, University Hospital Antwerp and University of Antwerp, Antwerp, Belgium
| | - G Pelosi
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
| | - F Penault-Llorca
- Department of Pathology, Clermont Auvergne University, "Molecular Imaging and Theranostic Strategies", Center Jean Perrin, Montalembert, Clermont-Ferrand, France
| | - T Picot
- Department of Pathology, University Hospital of Saint-Etienne, Saint-Etienne, France
| | - N Piton
- Department of Pathology, Rouen University Hospital, France and Normandie University, UNIROUEN, Inserm U1245, Rouen, France
| | - A Pittaro
- Division of Pathology, University Hospital Città Della Salute, Turin, Italy
| | - G Planchard
- Department of Pathology, CHU de Caen Côte de Nacre, Caen, France
| | - N Poté
- Department of Pathology, Hospital Bichat Bichat, Assistance Publique Hôpitaux de Paris; Université Paris Cité, Paris, France
| | - T Radonic
- Department of Pathology, Amsterdam University Medical Center, VUMC, University of Amsterdam, Amsterdam, Netherlands
| | - I Rapa
- Pathology Unit, San Luigi Hospital, Orbassano Turin, Italy
| | - A Rappa
- Oncogenomics Unit, European Institute of Oncology (IEO), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy
| | - C Roma
- Cell Biology and Biotherapy Unit, INT-Fondazione Pascale, Via M. Semmola, Naples, Italy
| | - M Rot
- Department of Pathology, University Clinic Golnik, Golnik, Slovenia
| | - J C Sabourin
- Department of Pathology, Rouen University Hospital, France and Normandie University, UNIROUEN, Inserm U1245, Rouen, France
| | - I Salmon
- Department of Pathology, Erasme Hospital, HUB ULB, Brussels, Belgium; CurePath, Jumet, Belgium
| | - S Savic Prince
- Department of Pathology, Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland
| | - A Scarpa
- Department of Diagnostics and Public Health, Section of Pathology, University and Hospital Trust of Verona, Verona, Italy
| | - E Schuuring
- Department of Pathology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
| | - I Serre
- Department of Pathology, Gui de Chauliac Hospital, Montpellier University Medical Center, University of Montpellier, 80 Avenue Augustin Fliche, Montpellier, France
| | - V Siozopoulou
- Department of Pathology, University Hospital Antwerp and University of Antwerp, Antwerp, Belgium
| | - D Sizaret
- Department of Pathology, CHRU Tours - Hôpital Trousseau, Chambray-lès-Tours, France
| | - S Smojver-Ježek
- Division for Pulmonary Cytology, Department of Pathology and Cytology, University Hospital Centre Zagreb, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - J Solassol
- Solid Tumour Laboratory, Pathology and Oncobiology Department, CHU Montpellier, University of Montpellier, Montpellier, France
| | - K Steinestel
- Institute of Pathology and Molecular Pathology, Bundeswehrkrankenhaus Ulm, Oberer Eselsberg 40, 89081 Ulm, Germany
| | - J Stojšić
- Department of Thoracic Pathology, Section of Pathology, University Clinical Centre of Serbia, Belgrade, Serbia
| | - C Syrykh
- Department of Pathology, IUC-T-Oncopole, Toulouse, France
| | - S Timofeev
- Multidisciplinary Clinical Center "Kommunarka" of the Moscow Health Department, Moscow, Russia
| | - G Troncone
- Department of Pathology, University of Oradea, Oradea, Romania
| | - A Uguen
- Department of Pathological Anatomy and Cytology, CHRU de Brest, Brest, France; LBAI, UMR1227, INSERM, University of Brest, CHU de Brest, Brest, France
| | - S Valmary-Degano
- Department of Pathology, Institute for Advanced Biosciences, CHU Grenoble Alpes, Université Grenoble Alpes, Grenoble, France
| | - A Vigier
- Department of Pathology, IUC-T-Oncopole, Toulouse, France
| | - M Volante
- Department of Oncology, University of Turin, San Luigi Hospital, Orbassano, Turin, Italy
| | - S G F Wahl
- Department of Pathology, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway
| | - A Stenzinger
- Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany; Translational Lung Research Center Heidelberg (TLRC-H), member of the German Center for Lung Research (DZL), Heidelberg, Germany
| | - M Ilié
- Laboratory of Clinical and Experimental Pathology, FHU OncoAge, Biobank Côte d'Azur BB-0033-00025, Louis Pasteur Hospital, IRCAN, Université Côte d'Azur, Nice, France
| |
Collapse
|
2
|
Stackowicz J, Gillis CM, Godon O, Iannascoli B, Conde E, Leveque E, Worrall WPM, Galli SJ, Bruhns P, Reber LL, Jönsson F. Conditional neutrophil depletion challenges their contribution to mouse models of anaphylaxis. Allergy 2023; 78:2767-2770. [PMID: 37022292 DOI: 10.1111/all.15738] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2023] [Revised: 03/19/2023] [Accepted: 04/03/2023] [Indexed: 04/07/2023]
Affiliation(s)
- Julien Stackowicz
- Unit of Antibodies in Therapy and Pathology, INSERM UMR1222, Institut Pasteur, Université de Paris Cité, Paris
- College Doctoral, Sorbonne Université, Paris, France
| | - Caitlin M Gillis
- Unit of Antibodies in Therapy and Pathology, INSERM UMR1222, Institut Pasteur, Université de Paris Cité, Paris
| | - Ophélie Godon
- Unit of Antibodies in Therapy and Pathology, INSERM UMR1222, Institut Pasteur, Université de Paris Cité, Paris
| | - Bruno Iannascoli
- Unit of Antibodies in Therapy and Pathology, INSERM UMR1222, Institut Pasteur, Université de Paris Cité, Paris
| | - Eva Conde
- Unit of Antibodies in Therapy and Pathology, INSERM UMR1222, Institut Pasteur, Université de Paris Cité, Paris
- College Doctoral, Sorbonne Université, Paris, France
| | - Edouard Leveque
- Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM UMR1291, CNRS UMR5051, University Toulouse III, Toulouse, France
| | - William P M Worrall
- Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM UMR1291, CNRS UMR5051, University Toulouse III, Toulouse, France
| | - Stephen J Galli
- Departments of Pathology and of Microbiology and Immunology, Sean N. Parker Center for Allergy and Asthma Research, Stanford University School of Medicine, Stanford, California, USA
| | - Pierre Bruhns
- Unit of Antibodies in Therapy and Pathology, INSERM UMR1222, Institut Pasteur, Université de Paris Cité, Paris
| | - Laurent L Reber
- Unit of Antibodies in Therapy and Pathology, INSERM UMR1222, Institut Pasteur, Université de Paris Cité, Paris
- Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM UMR1291, CNRS UMR5051, University Toulouse III, Toulouse, France
| | - Friederike Jönsson
- Unit of Antibodies in Therapy and Pathology, INSERM UMR1222, Institut Pasteur, Université de Paris Cité, Paris
- CNRS, Paris, France
| |
Collapse
|
3
|
Lamanna E, Conde E, Mougel A, Bonnefoy J, Colaone F, Godon O, Hamdi S, Kamphuis JBJ, Drouet B, Serra V, Bruhns P, Reber LL. A vaccine targeting human IL-4 and IL-13 protects against asthma in humanized mice. Allergy 2023. [PMID: 36799426 DOI: 10.1111/all.15680] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2022] [Revised: 01/16/2023] [Accepted: 02/05/2023] [Indexed: 02/18/2023]
Affiliation(s)
- Emma Lamanna
- Institut Pasteur, Université de Paris Cité, Inserm UMR 1222, Unit of Antibodies in Therapy and Pathology, Paris, France.,Neovacs SA, Suresnes, France
| | - Eva Conde
- Institut Pasteur, Université de Paris Cité, Inserm UMR 1222, Unit of Antibodies in Therapy and Pathology, Paris, France.,Neovacs SA, Suresnes, France.,Sorbonne Université, College Doctoral, Paris, France
| | - Aurélie Mougel
- Neovacs SA, Suresnes, France.,Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM UMR1291, CNRS UMR5051, University Toulouse III, Toulouse, France
| | | | | | - Ophélie Godon
- Institut Pasteur, Université de Paris Cité, Inserm UMR 1222, Unit of Antibodies in Therapy and Pathology, Paris, France
| | | | - Jasper B J Kamphuis
- Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM UMR1291, CNRS UMR5051, University Toulouse III, Toulouse, France
| | | | | | - Pierre Bruhns
- Institut Pasteur, Université de Paris Cité, Inserm UMR 1222, Unit of Antibodies in Therapy and Pathology, Paris, France
| | - Laurent L Reber
- Neovacs SA, Suresnes, France.,Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM UMR1291, CNRS UMR5051, University Toulouse III, Toulouse, France
| |
Collapse
|
4
|
Todorova B, Godon O, Conde E, Gillis CM, Iannascoli B, Richard-Le Goff O, Fiole D, Roumenina LT, Leusen JHW, Murphy AJ, Macdonald LE, Reber LL, Jönsson F, Bruhns P. IgG Subclass-Dependent Pulmonary Antigen Retention during Acute IgG-Dependent Systemic Anaphylaxis in Mice. The Journal of Immunology 2022; 209:1243-1251. [DOI: 10.4049/jimmunol.2200234] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/31/2022] [Accepted: 07/25/2022] [Indexed: 01/04/2023]
Abstract
Abstract
Mouse models of active systemic anaphylaxis rely predominantly on IgG Abs forming IgG–allergen immune complexes that induce IgG receptor–expressing neutrophils and monocytes/macrophages to release potent mediators, leading to systemic effects. Whether anaphylaxis initiates locally or systemically remains unknown. In this study, we aimed at identifying the anatomical location of IgG–allergen immune complexes during anaphylaxis. Active systemic anaphylaxis was induced following immunization with BSA and i.v. challenge with fluorescently labeled BSA. Ag retention across different organs was examined using whole-body fluorescence imaging, comparing immunized and naive animals. Various mouse models and in vivo deletion strategies were employed to determine the contribution of IgG receptors, complement component C1q, myeloid cell types, and anaphylaxis mediators. We found that following challenge, Ag diffused systemically, but specifically accumulated in the lungs of mice sensitized to that Ag, where it formed large Ab-dependent aggregates in the vasculature. Ag retention in the lungs did not rely on IgG receptors, C1q, neutrophils, or macrophages. IgG2a-mediated, but neither IgG1- nor IgG2b-mediated, passive systemic anaphylaxis led to Ag retention in the lung. Neutrophils and monocytes significantly accumulated in the lungs after challenge and captured high amounts of Ag, which led to downmodulation of surface IgG receptors and triggered their activation. Thus, within minutes of systemic injection in sensitized mice, Ag formed aggregates in the lung and liver vasculature, but accumulated specifically and dose-dependently in the lung. Neutrophils and monocytes recruited to the lung captured Ag and became activated. However, Ag aggregation in the lung vasculature was not necessary for anaphylaxis induction.
Collapse
Affiliation(s)
- Biliana Todorova
- *Unit of Antibodies in Therapy and Pathology, Institut Pasteur, Université de Paris, INSERM UMR1222, Paris, France
| | - Ophélie Godon
- *Unit of Antibodies in Therapy and Pathology, Institut Pasteur, Université de Paris, INSERM UMR1222, Paris, France
| | - Eva Conde
- *Unit of Antibodies in Therapy and Pathology, Institut Pasteur, Université de Paris, INSERM UMR1222, Paris, France
| | - Caitlin M. Gillis
- *Unit of Antibodies in Therapy and Pathology, Institut Pasteur, Université de Paris, INSERM UMR1222, Paris, France
| | - Bruno Iannascoli
- *Unit of Antibodies in Therapy and Pathology, Institut Pasteur, Université de Paris, INSERM UMR1222, Paris, France
| | - Odile Richard-Le Goff
- *Unit of Antibodies in Therapy and Pathology, Institut Pasteur, Université de Paris, INSERM UMR1222, Paris, France
| | - Daniel Fiole
- †Unité Biothérapies Anti-Infectieuses et Immunité, Département Microbiologie et Maladies Infectieuses, Institut de Recherche Biomédicale des Armées, Brétigny sur Orge, France
- ‡Unit of Human Histopathology and Animal Models, Institut Pasteur, Université de Paris, Paris, France
| | - Lubka T. Roumenina
- §Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, Paris, France
| | | | | | | | - Laurent L. Reber
- *Unit of Antibodies in Therapy and Pathology, Institut Pasteur, Université de Paris, INSERM UMR1222, Paris, France
- #Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM UMR1291, CNRS UMR5051, University Toulouse III, Toulouse, France
| | - Friederike Jönsson
- *Unit of Antibodies in Therapy and Pathology, Institut Pasteur, Université de Paris, INSERM UMR1222, Paris, France
| | - Pierre Bruhns
- *Unit of Antibodies in Therapy and Pathology, Institut Pasteur, Université de Paris, INSERM UMR1222, Paris, France
| |
Collapse
|
5
|
Hernandez S, Rodriguez Carrillo J, Caminoa A, Benito A, Martinez R, Alonso M, Clave S, Arriola E, Esteban-Rodriguez I, De Castro J, Sansano I, Felip E, Abdulkader I, Garcia J, Rojo F, Domine M, Teixido C, Reguart N, Compañ D, Insa A, Mancheño N, Palanca S, Juan O, Baixeras N, Nadal E, Cebollero M, Calles A, Martin P, Salas C, Provencio M, Aranda I, Massuti B, Lopez-Vilaro L, Majem M, Garrido P, Paz-Ares L, Lopez-Rios F, Conde E. P2.07-02 RET Fusion Testing with FISH and Real-Time PCR: a Comparison with RNA-Based Next-Generation Sequencing in RET Positive NSCLC. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.228] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
6
|
Guilleminault L, Conde E, Reber LL. Pharmacological approaches to target type 2 cytokines in asthma. Pharmacol Ther 2022; 237:108167. [PMID: 35283171 DOI: 10.1016/j.pharmthera.2022.108167] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2021] [Revised: 02/17/2022] [Accepted: 03/07/2022] [Indexed: 02/06/2023]
Abstract
Asthma is the most common chronic lung disease, affecting more than 250 million people worldwide. The heterogeneity of asthma phenotypes represents a challenge for adequate assessment and treatment of the disease. However, approximately 50% of asthma patients present with chronic type 2 inflammation initiated by alarmins, such as IL-33 and thymic stromal lymphopoietin (TSLP), and driven by the TH2 interleukins IL-4, IL-5 and IL-13. These cytokines have therefore become important therapeutic targets in asthma. Here, we discuss current knowledge on the structure and functions of these cytokines in asthma. We review preclinical and clinical data obtained with monoclonal antibodies (mAbs) targeting these cytokines or their receptors, as well as novel strategies under development, including bispecific mAbs, designed ankyrin repeat proteins (DARPins), small molecule inhibitors and vaccines targeting type 2 cytokines.
Collapse
Affiliation(s)
- Laurent Guilleminault
- Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM UMR1291, CNRS UMR5051, University Toulouse III, 31024 Toulouse, France; Department of Respiratory Medicine, Toulouse University Hospital, Faculty of Medicine, Toulouse, France
| | - Eva Conde
- Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR 1222 INSERM, F-75015 Paris, France; Sorbonne University, ED394, F-75005 Paris, France
| | - Laurent L Reber
- Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM UMR1291, CNRS UMR5051, University Toulouse III, 31024 Toulouse, France.
| |
Collapse
|
7
|
Conde E, Serra V, Bruhns P, Reber LL. [A vaccine targeting the cytokines IL-4 and IL-13 protects against allergic asthma in mice]. Med Sci (Paris) 2022; 38:25-27. [PMID: 35060881 DOI: 10.1051/medsci/2021232] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- Eva Conde
- Unité des anticorps en thérapie et pathologie, Institut Pasteur, Inserm UMR1222, 75015 Paris, France - Neovacs SA, Paris, France
| | | | - Pierre Bruhns
- Unité des anticorps en thérapie et pathologie, Institut Pasteur, Inserm UMR1222, 75015 Paris, France
| | - Laurent L Reber
- Institut toulousain des maladies infectieuses et inflammatoires (Infinity), Inserm UMR1291, CNRS UMR5051, Université Paul Sabatier Toulouse III, 31024 Toulouse, France
| |
Collapse
|
8
|
Conde E, Bruhns P, Serra V, Reber LL. Development and preclinical evaluation of a vaccine targeting IL-4 and IL-13 for the treatment of allergic asthma. Allergy 2021; 76:3553-3555. [PMID: 34224596 DOI: 10.1111/all.14998] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2021] [Revised: 06/15/2021] [Accepted: 06/25/2021] [Indexed: 11/29/2022]
Affiliation(s)
- Eva Conde
- Institut Pasteur Unit of Antibodies in Therapy and Pathology UMR 1222 INSERM Paris France
- Neovacs SA Paris France
| | - Pierre Bruhns
- Institut Pasteur Unit of Antibodies in Therapy and Pathology UMR 1222 INSERM Paris France
| | | | - Laurent L. Reber
- Toulouse Institute for Infectious and Inflammatory Diseases (Infinity) INSERM UMR1291CNRS UMR5051University Toulouse III Toulouse France
| |
Collapse
|
9
|
Stackowicz J, Gaudenzio N, Serhan N, Conde E, Godon O, Marichal T, Starkl P, Balbino B, Roers A, Bruhns P, Jönsson F, Moguelet P, Georgin-Lavialle S, Broderick L, Hoffman HM, Galli SJ, Reber LL. Neutrophil-specific gain-of-function mutations in Nlrp3 promote development of cryopyrin-associated periodic syndrome. J Exp Med 2021; 218:212620. [PMID: 34477811 PMCID: PMC8421266 DOI: 10.1084/jem.20201466] [Citation(s) in RCA: 28] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2020] [Revised: 06/10/2021] [Accepted: 07/30/2021] [Indexed: 12/14/2022] Open
Abstract
Gain-of-function mutations in NLRP3 are responsible for a spectrum of autoinflammatory diseases collectively referred to as “cryopyrin-associated periodic syndromes” (CAPS). Treatment of CAPS patients with IL-1–targeted therapies is effective, confirming a central pathogenic role for IL-1β. However, the specific myeloid cell population(s) exhibiting inflammasome activity and sustained IL-1β production in CAPS remains elusive. Previous reports suggested an important role for mast cells (MCs) in this process. Here, we report that, in mice, gain-of-function mutations in Nlrp3 restricted to neutrophils, and to a lesser extent macrophages/dendritic cells, but not MCs, are sufficient to trigger severe CAPS. Furthermore, in patients with clinically established CAPS, we show that skin-infiltrating neutrophils represent a substantial biological source of IL-1β. Together, our data indicate that neutrophils, rather than MCs, can represent the main cellular drivers of CAPS pathology.
Collapse
Affiliation(s)
- Julien Stackowicz
- Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR 1222, Institut national de la santé et de la recherche médicale, Paris, France.,Sorbonne Université, Paris, France
| | - Nicolas Gaudenzio
- Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), Institut national de la santé et de la recherche médicale, UMR 1291, Centre National de la Recherche Scientifique, UMR 5051, University of Toulouse III, Toulouse, France
| | - Nadine Serhan
- Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), Institut national de la santé et de la recherche médicale, UMR 1291, Centre National de la Recherche Scientifique, UMR 5051, University of Toulouse III, Toulouse, France
| | - Eva Conde
- Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR 1222, Institut national de la santé et de la recherche médicale, Paris, France
| | - Ophélie Godon
- Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR 1222, Institut national de la santé et de la recherche médicale, Paris, France
| | - Thomas Marichal
- GIGA-Research and Faculty of Veterinary Medicine, Liège University, Liège, Belgium
| | - Philipp Starkl
- Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.,Research Laboratory of Infection Biology, Department of Medicine I, Medical University of Vienna, Vienna, Austria
| | - Bianca Balbino
- Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR 1222, Institut national de la santé et de la recherche médicale, Paris, France.,Sorbonne Université, Paris, France
| | - Axel Roers
- Institute for Immunology, Medical Faculty Carl Gustav Carus, University of Technology Dresden, Dresden, Germany
| | - Pierre Bruhns
- Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR 1222, Institut national de la santé et de la recherche médicale, Paris, France
| | - Friederike Jönsson
- Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR 1222, Institut national de la santé et de la recherche médicale, Paris, France
| | - Philippe Moguelet
- Faculty of Medicine, Sorbonne University, Tenon Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France
| | - Sophie Georgin-Lavialle
- Internal Medicine Department, Tenon Hospital, Assistance Publique - Hôpitaux de Paris, Sorbonne University, Paris, France
| | - Lori Broderick
- Division of Pediatric Allergy, Immunology and Rheumatology, University of California, San Diego, and Rady Children's Hospital, San Diego, CA
| | - Hal M Hoffman
- Division of Pediatric Allergy, Immunology and Rheumatology, University of California, San Diego, and Rady Children's Hospital, San Diego, CA
| | - Stephen J Galli
- Department of Pathology, Stanford University School of Medicine, Stanford, CA.,Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA.,Sean N. Parker Center for Allergy and Asthma Research, Stanford University School of Medicine, Stanford, CA
| | - Laurent L Reber
- Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR 1222, Institut national de la santé et de la recherche médicale, Paris, France.,Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), Institut national de la santé et de la recherche médicale, UMR 1291, Centre National de la Recherche Scientifique, UMR 5051, University of Toulouse III, Toulouse, France
| |
Collapse
|
10
|
Conde E, Hernandez S, Caminoa A, Benito A, Martinez R, Alonso M, Jimenez B, Boni V, Remon J, Pijuan L, Clave S, Arriola E, Esteban I, De Castro J, Sansano I, Felip E, Abdulkader I, Garcia J, Rojo F, Domine M, Teixido C, Reguart N, Compañ D, Insa A, Mancheño N, Palanca S, Juan O, Baixeras N, Nadal E, Cebollero M, Calles A, Martin P, Salas C, Provencio M, Aranda I, Massuti B, Lopez-Vilaro L, Majem M, Enguita A, Paz-Ares L, Garrido P, Lopez-Rios F. MA14.02 RET Fusion Testing in Advanced Non-Small Cell Lung Carcinoma Patients: the RETING Study. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.183] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
11
|
Kamphuis JBJ, Worrall WPM, Stackowicz J, Mougel A, Mauré E, Conde E, Bruhns P, Guilleminault L, Gaudenzio N, Chen J, Gentek R, Reber LL. Comment on "Tumor-initiating cells establish an IL-33-TGF-β niche signaling loop to promote cancer progression". Science 2021; 372:372/6538/eabf2022. [PMID: 33833094 DOI: 10.1126/science.abf2022] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2021] [Indexed: 12/18/2022]
Abstract
Taniguchi et al (Research Articles, 17 July 2020, p. 269) claim that the cytokine interleukin-33 induces accumulation of tumor-associated macrophages expressing the immunoglobulin E receptor FcεRI. Although these findings hold great therapeutic promise, we provide evidence that the anti-FcεRI antibody used in this study is not specific for FcεRI on macrophages, which raises concerns about the validity of some of the conclusions.
Collapse
Affiliation(s)
- Jasper B J Kamphuis
- Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM U1291, University of Toulouse, CNRS U5282, 31024 Toulouse, France
| | - William P M Worrall
- Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM U1291, University of Toulouse, CNRS U5282, 31024 Toulouse, France
| | - Julien Stackowicz
- Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERM, 75015 Paris, France.,Sorbonne Université, 75006 Paris, France
| | - Aurélie Mougel
- Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM U1291, University of Toulouse, CNRS U5282, 31024 Toulouse, France
| | - Emilie Mauré
- Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM U1291, University of Toulouse, CNRS U5282, 31024 Toulouse, France
| | - Eva Conde
- Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERM, 75015 Paris, France.,Sorbonne Université, 75006 Paris, France
| | - Pierre Bruhns
- Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERM, 75015 Paris, France
| | - Laurent Guilleminault
- Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM U1291, University of Toulouse, CNRS U5282, 31024 Toulouse, France.,Department of Respiratory Medicine, Toulouse University Hospital, Faculty of Medicine, 31059 Toulouse, France
| | - Nicolas Gaudenzio
- Unité de Différenciation Epithéliale et Autoimmunité Rhumatoïde (UDEAR), UMR 1056, INSERM, Université de Toulouse, 31059 Toulouse, France
| | - Jinmiao Chen
- Singapore Immunology Network, Agency for Science, Technology and Research, 138648 Singapore
| | - Rebecca Gentek
- Centre for Inflammation Research, University of Edinburgh, EH16 4TJ Edinburgh, UK
| | - Laurent L Reber
- Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM U1291, University of Toulouse, CNRS U5282, 31024 Toulouse, France. .,Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERM, 75015 Paris, France
| |
Collapse
|
12
|
Rincon L, Rodriguez-Serrano E, Gonzalez-Portilla P, Conde E, Sanmartin M, Jimenez-Mena M, Garcia-Bermejo M, Zamorano J. Predicting adverse ventricular remodelling and poor outcome after acute myocardial infarction by a distinctive miRNA signature. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1670] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction and aim
Adverse ventricular remodelling and heart failure (HF) are frequent complications of acute myocardial infarction (MI), but no reliable methods are currently available for prediction. MicroRNAs (miRNAs) can be used as biomarkers and they play a crucial role in multiple diseases onset and evolution. The aim of our study was to identify and validate a panel of serum miRNAs with differential expression in MI and test their prognostic ability to predict chronic HF.
Methods
Sequential approach with several models: 1) Initial selection of miRNAs by a 762 miRNA hybridization array with samples from 12 patients with acute MI and 10 age and sex-matched controls; 2) Validation of selected miRNAs in a prospective study with consecutive enrolment of patients with type 1 MI at the Cardiac ICU of a tertiary hospital; two independent cohorts were included (2013–2014 and 2017–2019) with clinical and CV imaging assessment at baseline and long-term follow-up; serum miRNAs and other biomarkers (BNP, NT-proBNP, troponin, etc) were studied; the composite HF-related outcome included HF hospitalizations and CV mortality; 30 age and sex-adjusted controls were studied for miRNAs comparison; miRNA signature study was completed with 3) in vitro model of hypoxia ±nutrient supply deprivation in H9C2 cardiomyocytes, 4) in vivo rat model of ischemia-reperfusion and 5) permanent coronary occlusion. All procedures were approved by the Ethics Committee (refs. 175/13 & 061/16), the Animals Ethics Committee (ref. 298/16) and complied with the Declaration of Helsinki. All patients provided written informed consent.
Results
14 miRNAs were initially identified with highest differentiation between MI and controls. In the validation study, 311 patients with MI were enrolled, mean age 60±15, 81% male; ST elevation MI 65%, GRACE risk score 144±45, Killip class ≥II 23%, LVEF<50% at discharge 46% and NT-proBNP 3091±5997 pg/ml. miR-210, miR-21, miR-23 and miR-221 discriminated between patients with more severe form of MI presentation by Killip class (figure 1-B); in addition, GRACE risk score statistically correlated with miR-21, miR-221, miR-27, miR-93, miR-23, miR-148, miR-107, miR-210 and miR-144. Among markers of acute HF, miR-21, miR-23, miR-27, miR-210 and miR-221 significantly correlated with NT-proBNP (figure 1-C) and BNP levels. In parallel, miR-210, miR-21, miR-23, miR-106, miR-221, miR-27 and miR-93 correlated with left ventricular ejection fraction (LVEF). Finally, miR-21, miR-23, miR-210 and miR-221 associated with patients' long-term survival free of long-term HF-related events. Both in vitro and in vivo experimental models served as confirmation of the importance of these outlined miRNAs in cardiomyocyte response to ischemic stress and ventricular remodelling.
Conclusions
We identified a signature of microRNAs associated with adverse ventricular remodelling and poor long-term outcome after MI, that could serve as biomarkers involved in HF progression.
Figure 1
Funding Acknowledgement
Type of funding source: Public grant(s) – National budget only. Main funding source(s): Instituto de Salud Carlos III
Collapse
Affiliation(s)
- L.M Rincon
- University Hospital Ramon y Cajal, Madrid, Spain
| | | | | | - E Conde
- University Hospital Ramon y Cajal, Madrid, Spain
| | - M Sanmartin
- University Hospital Ramon y Cajal, Madrid, Spain
| | | | | | - J.L Zamorano
- University Hospital Ramon y Cajal, Madrid, Spain
| |
Collapse
|
13
|
Salas-Benito D, De Andrea C, Aramendia J, Mancheño U, Elizalde E, Conde E, Tamayo I, Guillén F, Jurado M, Mínguez JÁ, Martín AG, Ponz-Sarvise M, Hervás-Stubbs S. Preselecting tumour-infiltrating lymphocyte subsets to implement adoptive immunotherapy in ovarian cancer. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz250.034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
14
|
López-Hortas L, Conde E, Falqué E, Domínguez H, Torres MD. Preparation of Hydrogels Composed of Bioactive Compounds from Aqueous Phase of Artichoke Obtained by MHG Technique. FOOD BIOPROCESS TECH 2019. [DOI: 10.1007/s11947-019-02301-2] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
|
15
|
Hernandez S, Angulo B, Dominguez C, Caminoa A, Muriel A, Alonso M, Jimenez L, Peñalver R, Collazo-Lorduy A, Jimenez B, Garrido P, Paz-Ares L, De Castro J, Conde E, Lopez-Rios F. P2.09-11 TMB Estimated with Targeted NGS in Early Stage Squamous Cell Carcinoma: Correlation with PD-L1 Expression and Lymphocyte Density. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1308] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
16
|
Balbino B, Conde E, Marichal T, Starkl P, Reber LL. Approaches to target IgE antibodies in allergic diseases. Pharmacol Ther 2018; 191:50-64. [PMID: 29909239 DOI: 10.1016/j.pharmthera.2018.05.015] [Citation(s) in RCA: 36] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2018] [Accepted: 05/08/2018] [Indexed: 12/26/2022]
Abstract
IgE is the antibody isotype found at the lowest concentration in the circulation. However IgE can undeniably play an important role in mediating allergic reactions; best exemplified by the clinical benefits of anti-IgE monoclonal antibody (omalizumab) therapy for some allergic diseases. This review will describe our current understanding of the interactions between IgE and its main receptors FcεRI and CD23 (FcεRII). We will review the known and potential functions of IgE in health and disease: in particular, its detrimental roles in allergic diseases and chronic spontaneous urticaria, and its protective functions in host defense against parasites and venoms. Finally, we will present an overview of the drugs that are in clinical development or have therapeutic potential for IgE-mediated allergic diseases.
Collapse
Affiliation(s)
- Bianca Balbino
- Institut Pasteur, Department of Immunology, Unit of Antibodies in Therapy and Pathology, Paris, France; INSERM, U1222, Paris, France; Université Pierre et Marie Curie, Paris, France
| | - Eva Conde
- Institut Pasteur, Department of Immunology, Unit of Antibodies in Therapy and Pathology, Paris, France; INSERM, U1222, Paris, France; Université Pierre et Marie Curie, Paris, France; Neovacs SA, Paris, France
| | - Thomas Marichal
- GIGA-Research and Faculty of Veterinary Medicine, University of Liege, 4000, Liege, Belgium; Walloon Excellence in Life Sciences and Biotechnology, Wallonia, Belgium
| | - Philipp Starkl
- CeMM, Research Center for Molecular Medicine of the Austrian Academy of Sciences, Austria; Department of Medicine I, Research Laboratory of Infection Biology, Medical University of Vienna, Vienna, Austria
| | - Laurent L Reber
- Institut Pasteur, Department of Immunology, Unit of Antibodies in Therapy and Pathology, Paris, France; INSERM, U1222, Paris, France.
| |
Collapse
|
17
|
Masterson EE, Fitzpatrick AL, Enquobahrie DA, Mancl LA, Eisenberg DT, Conde E, Hujoel PP. Dental enamel defects predict adolescent health indicators: A cohort study among the Tsimane' of Bolivia. Am J Hum Biol 2018; 30:e23107. [PMID: 29399912 PMCID: PMC5980689 DOI: 10.1002/ajhb.23107] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2017] [Revised: 12/15/2017] [Accepted: 01/19/2018] [Indexed: 12/22/2022] Open
Abstract
OBJECTIVES Bioarchaeological findings have linked defective enamel formation in preadulthood with adult mortality. We investigated how defective enamel formation in infancy and childhood is associated with risk factors for adult morbidity and mortality in adolescents. METHODS This cohort study of 349 Amerindian adolescents (10-17 years of age) related extent of enamel defects on the central maxillary incisors (none, less than 1/3, 1/3 to 2/3, more than 2/3) to adolescent anthropometrics (height, weight) and biomarkers (hemoglobin, glycated hemoglobin, white blood cell count, and blood pressure). Risk differences and 95% confidence intervals were estimated using multiple linear regression. Enamel defects and stunted growth were compared in their ability to predict adolescent health indicators using log-binomial regression and receiver operating characteristics (ROCs). RESULTS Greater extent of defective enamel formation on the tooth surface was associated with shorter height (-1.35 cm, 95% CI: -2.17, -0.53), lower weight (-0.98 kg, 95% CI: -1.70, -0.26), lower hemoglobin (-0.36 g/dL, 95% CI: -0.59, -0.13), lower glycated hemoglobin (-0.04 %A1c , 95% CI: -0.08, -0.00008), and higher white blood cell count (0.74 109 /L, 95% CI: 0.35, 1.14) in adolescence. Extent of enamel defects and stunted growth independently performed similarly as risk factors for adverse adolescent outcomes, including anemia, prediabetes/type II diabetes, elevated WBC count, prehypertension/hypertension, and metabolic health. CONCLUSIONS Defective enamel formation in infancy and childhood predicted adolescent health outcomes and may be primarily associated with infection. Extent of enamel defects and stunted growth may be equally predictive of adverse adolescent health outcomes.
Collapse
Affiliation(s)
- Erin E. Masterson
- University of Washington, School of Dentistry, Department of Oral Health Sciences, 1959 NE Pacific Street, Health Sciences Building D-322, Box 357475, Seattle, WA, 98119 USA
| | - Annette L. Fitzpatrick
- University of Washington, School of Public Health, Department of Epidemiology, 1959 NE Pacific Street, Health Science Building F-262, Box 357236, Seattle, WA, 98195 USA
| | - Daniel A. Enquobahrie
- University of Washington, School of Public Health, Department of Epidemiology, 1959 NE Pacific Street, Health Science Building F-262, Box 357236, Seattle, WA, 98195 USA
| | - Lloyd A. Mancl
- University of Washington, School of Dentistry, Department of Oral Health Sciences, 1959 NE Pacific Street, Health Sciences Building D-322, Box 357475, Seattle, WA, 98119 USA
| | - Dan T.A. Eisenberg
- University of Washington, Department of Anthropology, 314 Denny Hall, Box 353100, Seattle, WA 98195, USA
| | - E. Conde
- Centro Boliviano de Investigación y Desarollo Socio-Integral, Correo Central, San Borja, Beni, Bolivia
| | - Philippe P. Hujoel
- University of Washington, School of Dentistry, Department of Oral Health Sciences, 1959 NE Pacific Street, Health Sciences Building D-322, Box 357475, Seattle, WA, 98119 USA
- University of Washington, School of Public Health, Department of Epidemiology, 1959 NE Pacific Street, Health Science Building F-262, Box 357236, Seattle, WA, 98195 USA
| |
Collapse
|
18
|
Gonzalez-Barca E, Carrillo E, Grande C, Martín A, Montes-Moreno S, Coronado M, Mercadal S, Roncero J, Perez De Oteyza J, Nicolas C, Rodriguez-Salazar M, Sancho J, Palomera L, Lopez J, Albo C, Peñalver F, Hernandez J, Lopez-Guillermo A, Ramirez M, Jarque I, Bargay J, Canales M, Conde E, Caballero D. PHASE 2 RANDOMIZED TRIAL COMPARING STANDARD RCHOP VERSUS BRCAP AS FIRST LINE TREATMENT IN YOUNG PATIENTS WITH HIGH-RISK DLBCL. A STUDY FROM SPANISH GROUP GELTAMO. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_49] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- E. Gonzalez-Barca
- Hematology; Instituto Catalan De Oncologia-L'Hospitalet; Barcelona Spain
| | - E. Carrillo
- Hematology; H. Virgen Del Rocio; Sevilla Spain
| | - C. Grande
- Hematology, H. 12 De Octubre; Madrid Spain
| | - A. Martín
- Hematology; Complejo Hospitalario De Salamanca; Salamanca Spain
| | | | - M. Coronado
- Nuclear Medicine, H. U. La Paz; Madrid Spain
| | - S. Mercadal
- Hematology; Instituto Catalan De Oncologia-L'Hospitalet; Barcelona Spain
| | - J.M. Roncero
- Hematology; ICO Girona (H.U. Dr. Josep Trueta); Girona Spain
| | | | - C. Nicolas
- Hematology; H. U. Central De Asturias; Oviedo Spain
| | | | - J.M. Sancho
- Hematology; Ico Badalona (H. Germans Trias I Pujol); Barcelona Spain
| | - L. Palomera
- Hematology, H. C. U. Lozano Blesa; Zaragoza Spain
| | - J. Lopez
- Hematology, H. U. Ramón Y Cajal; Madrid Spain
| | - C. Albo
- Hematology, C.H.U De Vigo; Pontevedra Spain
| | | | | | | | - M.J. Ramirez
- Hematology, H. De Jerez, Jerez De La Frontera; Spain
| | - I. Jarque
- Hematology, H. U. Politècnic La Fe; Valencia Spain
| | - J. Bargay
- Hematology, H. Son Llàtzer; Palma Spain
| | | | - E. Conde
- Hematology, H. U. Marqués De Valdecilla; Santander Spain
| | - D. Caballero
- Hematology, H. U. Marqués De Valdecilla; Santander Spain
| |
Collapse
|
19
|
Salar A, Domingo-Domenech E, Panizo C, Nicolás C, Bargay J, Muntañola A, Canales M, Bello J, Sancho J, Tomás J, Rodriguez M, Peñalver F, Palomera L, Grande C, Sánchez-Blanco J, Arranz R, Conde E, Garcia M, García J, Caballero D, Montalbán C. LONG-TERM RESULTS OF THE MULTICENTER PHASE II TRIAL WITH BENDAMUSTINE AND RITUXIMAB AS FIRST LINE TREATMENT FOR PATIENTS WITH MALT LYMPHOMA (MALT-2008-01). Hematol Oncol 2017. [DOI: 10.1002/hon.2437_137] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- A. Salar
- Hematology; Hospital del Mar; Barcelona Spain
| | | | - C. Panizo
- Hematology; Clinica Universitaria Navarra; Pamplona Spain
| | - C. Nicolás
- Hematology; Hospital Central de Asturias; Oviedo Spain
| | - J. Bargay
- Hematology; Hospital Son Llatzer; Palma Mallorca Spain
| | | | - M. Canales
- Hematology; Hospital La Paz; Madrid Spain
| | - J. Bello
- Hematology; Hospital de Santiago Compostela; Santiago de Compostela Spain
| | - J. Sancho
- Hematology; ICO Badalona; Badalona Spain
| | - J. Tomás
- Hematology; MD Anderson Cancer Center; Madrid Spain
| | - M. Rodriguez
- Hematology; Hospital U de Canarias; Tenerife Spain
| | | | - L. Palomera
- Hematology; Hospital Clínico Lozano Blesa; Zaragoza Spain
| | - C. Grande
- Hematology; Hospital 12 de Octubre; Madrid Spain
| | | | - R. Arranz
- Hematology; Hospital de la Princesa; Madrid Spain
| | - E. Conde
- Hematology; Hospital Marqués de Valdecilla; Santander Spain
| | - M. Garcia
- Hematology; Hospital del Mar; Barcelona Spain
| | - J.F. García
- Hematology; MD Anderson Cancer Center; Madrid Spain
| | - D. Caballero
- Hematology; Hospital de Salamanca; Salamanca Spain
| | - C. Montalbán
- Hematology; MD Anderson Cancer Center; Madrid Spain
| |
Collapse
|
20
|
García-Noblejas A, Cannata-Ortiz J, Conde E, González Barca E, Gutiérrez N, Rojas R, Vidal MJ, Ramírez MJ, Jiménez-Ubieto A, García-Ruiz JC, Sancho JM, López A, Ríos Rull P, Novelli S, Albo C, Debén G, López-Guillermo A, Nicolás C, González de Villambrosia S, Mercadal S, Martín García-Sancho A, Arranz R. Autologous stem cell transplantation (ASCT) in patients with mantle cell lymphoma: a retrospective study of the Spanish lymphoma group (GELTAMO). Ann Hematol 2017; 96:1323-1330. [PMID: 28536895 DOI: 10.1007/s00277-017-2998-6] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2016] [Accepted: 04/10/2017] [Indexed: 01/21/2023]
Abstract
Guidelines recommend autologous stem cell transplantation (ASCT) consolidation in first complete or partial response after regimens including rituximab (R) and high-dose AraC (HDAC), but its use beyond that response is questioned. We present a retrospective analysis of 268 patients with MCL who received ASCT. With a median follow-up for survival patients of 54 months, progression-free survival and overall survival for the whole series were 38 and 74 months, respectively, and for patients transplanted in first CR 49 and 97 months, respectively. Patients without CR before transplant were analyzed separately, those who achieved CR after transplantation had better PFS (48 vs 0.03 months, p < 0.001) and OS (92 vs 16 months, p < 0.001) than the remaining. In univariate analysis, first CR at transplant (p = 0.01) and prior rituximab (p = 0.02) were the variables associated with PFS. For OS, the same variables resulted significant (p = 0.03 and p < 0.001, respectively). In multivariate analysis, only the status at transplant (first CR) remained significant. This retrospective study concludes that ASCT consolidation in first CR induces high survival rates. In other stages of disease, the need of ASCT as consolidation may be questioned.
Collapse
Affiliation(s)
- A García-Noblejas
- Hospital Universitario La Princesa, Diego de Leon, 62, 28006, Madrid, Spain
| | - J Cannata-Ortiz
- Hospital Universitario La Princesa, Diego de Leon, 62, 28006, Madrid, Spain
| | - E Conde
- HU Marqués de Valdecilla, Santander, Spain
| | | | | | - R Rojas
- HU Reina Sofía, Córdoba, Spain
| | | | | | | | | | - J M Sancho
- H. Germans Trias i Pujol, Barcelona, Spain
| | - A López
- HU Vall d'Hebron, Barcelona, Spain
| | - P Ríos Rull
- HU Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Spain
| | | | - C Albo
- H Xeral-Cíes, Madrid, Spain
| | | | | | - C Nicolás
- HU Central de Asturias, Oviedo, Spain
| | | | - S Mercadal
- Instituto Catalán de Oncología, Barcelona, Spain
| | | | - R Arranz
- Hospital Universitario La Princesa, Diego de Leon, 62, 28006, Madrid, Spain.
| |
Collapse
|
21
|
De La Serna J, Sanz J, Bermúdez A, Cabrero M, Serrano D, Vallejo C, Gómez V, Moraleda JM, Perez SG, Caballero MD, Conde E, Lahuerta JJ, Sanz G. Toxicity and efficacy of busulfan and fludarabine myeloablative conditioning for HLA-identical sibling allogeneic hematopoietic cell transplantation in AML and MDS. Bone Marrow Transplant 2016; 51:961-6. [PMID: 26950372 DOI: 10.1038/bmt.2016.42] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2015] [Revised: 11/17/2015] [Accepted: 11/19/2015] [Indexed: 12/26/2022]
Abstract
The safety and efficacy of a 4-day myeloablative conditioning (MAC) regimen consisting of Bu 3.2 mg/kg and fludarabine 40 mg/m(2)/day for HLA-identical sibling allogeneic hematopoietic cell transplantation (HCT) in myeloid malignancies was investigated in 133 patients (median age, 47 years; range 19-74 years) with de novo AML (60%), secondary AML (20%) or myelodysplastic syndrome (20%). All patients engrafted. Hepatic veno-occlusive disease occurred in five patients (4%), and severe toxicities, mostly mucositis, occurred in twenty-three (17%) patients. The non-relapse mortality (NRM) at 100 days was 1.5%. The incidences of acute GVHD grade 2-4 and grade 3-4 were 32 and 13%, respectively. At a median follow-up of 38 months, the cumulative incidence of chronic GVHD was 67%. The relapse incidence was 30% (27 and 31%, respectively, in patients with early- and late-stage disease), and the overall NRM was 15%. The actuarial 4-year disease-free survival (DFS) and overall survival (OS) were 54 and 62%, respectively. Patients aged <50 years had better outcomes compared with older patients (DFS 64 vs 42%, P=0.006; OS 73 vs 47%, P<0.001, respectively).
Collapse
Affiliation(s)
- J De La Serna
- Hematology Department, Servicio de Hematología, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - J Sanz
- Hematology Department, Hospital Universitario La Fe, Valencia, Spain
| | - A Bermúdez
- Hematology Department, Hospital Universitario Marques de Valdecilla, Santander, Spain
| | - M Cabrero
- Hematology Department, Hospital Universitario Clínico de Salamanca, Salamanca, Spain
| | - D Serrano
- Hematology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain
| | - C Vallejo
- Hematology Department, Hospital Universitario Central de Asturias, Oviedo, Spain
| | - V Gómez
- Hematology Department, Hospital Universitario de la Princesa, Madrid, Spain
| | - J M Moraleda
- Hematology Department, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain
| | - S G Perez
- Hematology Department, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain
| | - M D Caballero
- Hematology Department, Hospital Universitario Clínico de Salamanca, Salamanca, Spain
| | - E Conde
- Hematology Department, Hospital Universitario Marques de Valdecilla, Santander, Spain
| | - J J Lahuerta
- Hematology Department, Servicio de Hematología, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - G Sanz
- Hematology Department, Hospital Universitario La Fe, Valencia, Spain
| |
Collapse
|
22
|
Almeida Leite R, Gama Pereira C, Conde E, Queirós Santos T, Almeida M, Azevedo Santos T, Mesquita Figueiredo A. Dementia due to HIV infection: Case report. Eur Psychiatry 2016. [DOI: 10.1016/j.eurpsy.2016.01.1327] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
23
|
Almeida Leite R, Conde E, Queirós Santos T, Almeida M, Azevedo Santos T, Mesquita Figueiredo A. Obsessive Versus Delusional Jealousy: Destruction in a Form of Creation – A Review. Eur Psychiatry 2016. [DOI: 10.1016/j.eurpsy.2016.01.1966] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
Abstract
IntroductionJealousy is a complex emotional state and some degree is considered normal in mature love, but when does it become destructive in a relationship? There's a thin line between what is normal and what is pathologic. Pathological jealousy differs from normal by its intensity and irrationality. Obsessive and delusional jealousies are different types of pathological jealousy, difficult to distinguish, which is important, since they have different treatment. Despite the differences, both result in significant distress and carry the risk of homicide/suicide, so it's a matter deserving the psychiatrists’ attention.ObjectiveExplore the psychopathological differences between obsessive and delusional jealousy and list the characteristics and difficulties in the approach to pathological jealousy.MethodsThe results were obtained searching literature included on the PubMed and Google Scholar platforms.ResultsDelusional jealousy is characterized by strong and false beliefs that the partner is unfaithful. Individuals with obsessive jealousy suffer from unpleasant and irrational jealous ruminations that the partner could be unfaithful, accompanied by compulsive checking of partners’ behavior. This jealousy resembles obsessive-compulsive phenomenology and should be treated with SSRIs and cognitive-behavioral therapy. Delusional jealousy is a psychotic disorder and should be treated with antipsychotics.ConclusionThe common issue in pathological jealousy is the problem of adherence to treatment and bad prognosis. In order to achieve better treatment outcomes, we should follow-up the patient regularly. One key factor is to explore the psychopathology and motivate the sufferer for the proper pharmacological and psychotherapeutic interventions, trying to reduce the suffering caused by ideas of unfaithfulness.Disclosure of interestThe authors have not supplied their declaration of competing interest.
Collapse
|
24
|
Yáñez L, Insunza A, Ibarrondo P, de Miguel C, Bermúdez A, Colorado M, López-Duarte M, Richard C, Conde E. Experience with anidulafungin in patients with allogeneic hematopoietic stem cell transplantation and graft-versus-host disease. Transpl Infect Dis 2015; 17:761-7. [PMID: 26250790 DOI: 10.1111/tid.12429] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2015] [Revised: 05/29/2015] [Accepted: 07/19/2015] [Indexed: 12/01/2022]
Abstract
BACKGROUND It is well known that both acute and chronic graft-versus-host disease (GVHD) are associated with invasive fungal disease (IFD). Because the galactomannan antigen diagnostic test has low specificity and sensitivity outside of the neutropenic period, many institutions use posaconazole or voriconazole for IFD prophylaxis during GVHD treatment. Moreover, several factors, mainly hepatic impairment, can limit the use of extended spectrum azoles, both in prophylaxis or treatment. METHODS We retrospectively analyzed 25 patients with allogeneic hematopoietic stem cell transplantation (HSCT) and GVHD - grade III-IV acute GHVD (n = 15), progressive chronic GVHD (n = 7), and "overlap" GVHD (n = 3) - who received intravenous anidulafungin (200 mg on day 1, followed by 100 mg once daily). If necessary, anidulafungin treatment was followed by oral administration of 200 mg voriconazole twice a day or 200 mg posaconazole 3 times daily until patients were considered not at risk for IFD. RESULTS Twenty-one patients (85%) received anidulafungin as prophylaxis and 5 patients (15%) received it as treatment. Median duration of intravenous anidulafungin administration was 8 days (range 6-17). Seven patients (28%) presented mild adverse effects, with no significant interactions with calcineurin inhibitors. Sequentially, 4 patients received voriconazole and 6 posaconazole. Two patients (8%) developed IFD after anidulafungin withdrawal: 1 with Candida albicans and the other with Mucor, 8 and 5 days after withdrawal, respectively. CONCLUSIONS Our results are of interest owing to the absence of data in the literature on anidulafungin use in HSCT patients with GVHD, and suggest that anidulafungin, because of its spectrum, pharmacological profile, low toxicity, and absence of interactions with immunosuppressants, could be a drug of choice in this setting.
Collapse
Affiliation(s)
- L Yáñez
- Hematology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - A Insunza
- Hematology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - P Ibarrondo
- Hematology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - C de Miguel
- Hematology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - A Bermúdez
- Hematology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - M Colorado
- Hematology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - M López-Duarte
- Hematology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - C Richard
- Hematology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - E Conde
- Hematology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| |
Collapse
|
25
|
Valdivielso-Ramos M, Burdaspal A, Conde E, de la Cueva P. Balloon-cell variant of the Spitz nevus. J Eur Acad Dermatol Venereol 2015; 30:1621-2. [DOI: 10.1111/jdv.13207] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2015] [Accepted: 03/06/2015] [Indexed: 11/29/2022]
Affiliation(s)
| | - A. Burdaspal
- Pathology Department; Hospital Infanta Leonor; Madrid Spain
| | - E. Conde
- Dermatology Department; Hospital Infanta Leonor; Madrid Spain
| | - P. de la Cueva
- Dermatology Department; Hospital Infanta Leonor; Madrid Spain
| |
Collapse
|
26
|
Santos T, Conde E, Alcafache J, Santos V. Reasons and Factors for Rapid Psychiatry Readmissions: an Analysis over a 36 Months Period. Eur Psychiatry 2015. [DOI: 10.1016/s0924-9338(15)32120-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
27
|
Lameira AP, Pereira A, Conde E, Gawryszewski LG. Interaction between affordance and handedness recognition: a chronometric study. ACTA ACUST UNITED AC 2015; 48:316-20. [PMID: 25714894 PMCID: PMC4418361 DOI: 10.1590/1414-431x20144336] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2014] [Accepted: 11/04/2014] [Indexed: 11/22/2022]
Abstract
The visualization of tools and manipulable objects activates motor-related areas in
the cortex, facilitating possible actions toward them. This pattern of activity may
underlie the phenomenon of object affordance. Some cortical motor neurons are also
covertly activated during the recognition of body parts such as hands. One hypothesis
is that different subpopulations of motor neurons in the frontal cortex are activated
in each motor program; for example, canonical neurons in the premotor cortex are
responsible for the affordance of visual objects, while mirror neurons support motor
imagery triggered during handedness recognition. However, the question remains
whether these subpopulations work independently. This hypothesis can be tested with a
manual reaction time (MRT) task with a priming paradigm to evaluate whether the view
of a manipulable object interferes with the motor imagery of the subject's hand. The
MRT provides a measure of the course of information processing in the brain and
allows indirect evaluation of cognitive processes. Our results suggest that canonical
and mirror neurons work together to create a motor plan involving hand movements to
facilitate successful object manipulation.
Collapse
Affiliation(s)
- A P Lameira
- Unidade Acadêmica Ciências da Vida, Universidade Federal de Campina Grande, Cajazeiras, PB, Brasil
| | - A Pereira
- Instituto do Cérebro, Universidade Federal do Rio Grande do Norte, Natal, RN, Brasil
| | - E Conde
- Departamento de Psicologia, Universidade Federal de Pernambuco, Recife, PE, Brasil
| | - L G Gawryszewski
- Programa de Pós-graduação em Neurociências, Instituto de Biologia, Universidade Federal Fluminense, Niterói, RJ, Brasil
| |
Collapse
|
28
|
Pascual L, Barrena M, Gómez de Salazar J, Soria A, Fernández M, Conde E, Quiñones J. Determination of the protective atmosphere during the Pb–Li alloy remelting. Fusion Engineering and Design 2014. [DOI: 10.1016/j.fusengdes.2014.03.065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
29
|
Pascual L, Barrena M, Gómez de Salazar J, Soria A, Fernández M, Conde E, Quiñones J. Production of different eutectic Pb–Li alloys in Spain. Fusion Engineering and Design 2014. [DOI: 10.1016/j.fusengdes.2014.03.062] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
30
|
Bordell A, Calatrava J, Conde E, de la Rosa D. AB1180-HPR Can an Intervention over the Health Workers at A Primary Health Care Center Improve the Quality of Patients Diagnosed of Osteoarthritis' Clinic History? Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.5972] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
31
|
|
32
|
Klukowska M, Grender JM, Conde E, Ccahuana-Vasquez RA, Goyal CR. A randomized 12-week clinical comparison of an oscillating-rotating toothbrush to a new sonic brush in the reduction of gingivitis and plaque. J Clin Dent 2014; 25:26-31. [PMID: 25122979] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
OBJECTIVE To evaluate the efficacy of a marketed oscillating-rotating (O-R) power toothbrush (Oral-B Triumph with SmartGuide and FlossAction brush head, D34/EB25) to a new sonic toothbrush (Sonicare FlexCare Platinum) in the reduction of gingivitis and plaque over a 12-week test period. METHODS This was a single center, randomized, open label, examiner-blind, two-treatment, parallel group study. Subjects who met the entrance criteria were enrolled in the study and randomly assigned to either the O-R or sonic treatment group. Subjects brushed with their assigned toothbrush and a marketed fluoride dentifrice for two minutes twice daily at home for 12 weeks. Gingivitis and plaque were evaluated at Baseline, Week 6, and Week 12. Gingivitis was assessed using the Modified Gingival Index (MGI) and Gingival Bleeding Index (GBI), and plaque was assessed using the Rustogi Modified Navy Plaque Index (RMNPI). Data were analyzed using an Analysis of Covariance (ANCOVA) with Baseline as the covariate. RESULTS In total, 130 subjects (65 per group) were randomized to treatment and 127 subjects completed the study. Both brushes produced statistically significant (p < 0.001) reductions in gingivitis and plaque measures relative to Baseline. At Week 12, the O-R brush demonstrated significantly greater reductions than the sonic brush in whole mouth gingivitis measures (p = 0.007). Additionally, the O-R brush presented significantly fewer bleeding sites (p < 0.007) and significantly greater reductions in whole mouth plaque measures (p < or = 0.035) at Weeks 6 and 12 versus the sonic brush. The benefit for the O-R brush versus the sonic brush at Week 12 was 11.7% for gingivitis, 19.8% for number of bleeding sites, and 12.2% for whole mouth plaque. There were no adverse events reported or observed for either brush. CONCLUSION The oscillating-rotating toothbrush demonstrated statistically significantly greater reductions in whole mouth plaque at Weeks 6 and 12, as well as significantly greater gingivitis reductions over the long-term (12 weeks), compared to the new sonic toothbrush.
Collapse
|
33
|
Conde E, Angulo B, Izquierdo E, Paz-Ares L, Belda-Iniesta C, Hidalgo M, López-Ríos F. Lung adenocarcinoma in the era of targeted therapies: histological classification, sample prioritization, and predictive biomarkers. Clin Transl Oncol 2013; 15:503-8. [PMID: 23359174 PMCID: PMC3695315 DOI: 10.1007/s12094-012-0983-z] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2012] [Accepted: 11/27/2012] [Indexed: 01/10/2023]
Abstract
The arrival of targeted therapies has presented both a conceptual and a practical challenge in the treatment of patients with advanced non-small cell lung carcinomas (NSCLCs). The relationship of these treatments with specific histologies and predictive biomarkers has made the handling of biopsies the key factor for success. In this study, we highlight the balance between precise histological diagnosis and the practice of conducting multiple predictive assays simultaneously. This can only be achieved where there is a commitment to multidisciplinary working by the tumor board to ensure that a sensible protocol is applied. This proposal for prioritizing samples includes both recent technological advances and the some of the latest discoveries in the molecular classification of NSCLCs.
Collapse
Affiliation(s)
- E. Conde
- Laboratorio de Dianas Terapéuticas, Centro Integral Oncológico Clara Campal, Hospital Universitario Madrid Sanchinarro, Faculty of Medicine, Universidad San Pablo-CEU, Madrid, Spain
| | - B. Angulo
- Laboratorio de Dianas Terapéuticas, Centro Integral Oncológico Clara Campal, Hospital Universitario Madrid Sanchinarro, Faculty of Medicine, Universidad San Pablo-CEU, Madrid, Spain
| | - E. Izquierdo
- Laboratorio de Dianas Terapéuticas, Centro Integral Oncológico Clara Campal, Hospital Universitario Madrid Sanchinarro, Faculty of Medicine, Universidad San Pablo-CEU, Madrid, Spain
| | - L. Paz-Ares
- Department of Oncology, Instituto de Biomedicina de Sevilla (IBIS) and Hospital Universitario Virgen del Rocío, Sevilla, Spain
| | - C. Belda-Iniesta
- Department of Oncology, Centro Integral Oncológico Clara Campal, Hospital Universitario Madrid Sanchinarro, Faculty of Medicine, Universidad San Pablo-CEU, Madrid, Spain
| | - M. Hidalgo
- Department of Oncology, Centro Integral Oncológico Clara Campal, Hospital Universitario Madrid Sanchinarro, Faculty of Medicine, Universidad San Pablo-CEU, Madrid, Spain
| | - F. López-Ríos
- Laboratorio de Dianas Terapéuticas, Centro Integral Oncológico Clara Campal, Hospital Universitario Madrid Sanchinarro, Faculty of Medicine, Universidad San Pablo-CEU, Madrid, Spain
| |
Collapse
|
34
|
Rodríguez-Moreno JF, Conde E, Duran I. [Solitary fibrous tumor of the renal hilum: a rare a diagnosis for a not so rare clinical picture]. Actas Urol Esp 2012; 36:505-6. [PMID: 22819347 DOI: 10.1016/j.acuro.2012.03.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2012] [Accepted: 03/07/2012] [Indexed: 11/28/2022]
|
35
|
Cortés-Sempere M, de Miguel MP, Pernía O, Rodriguez C, de Castro Carpeño J, Nistal M, Conde E, López-Ríos F, Belda-Iniesta C, Perona R, Ibanez de Caceres I. IGFBP-3 methylation-derived deficiency mediates the resistance to cisplatin through the activation of the IGFIR/Akt pathway in non-small cell lung cancer. Oncogene 2012; 32:1274-83. [PMID: 22543588 DOI: 10.1038/onc.2012.146] [Citation(s) in RCA: 53] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Although many cancers initially respond to cisplatin (CDDP)-based chemotherapy, resistance frequently develops. Insulin-like growth factor-binding protein-3 (IGFBP-3) silencing by promoter methylation is involved in the CDDP-acquired resistance process in non-small cell lung cancer (NSCLC) patients. Our purpose is to design a translational-based profile to predict resistance in NSCLC by studying the role of IGFBP-3 in the phosphatidyl inositol 3-kinase (PI3K) signaling pathway. We have first examined the relationship between IGFBP-3 expression regulated by promoter methylation and activation of the epidermal growth factor receptor (EGFR), insulin-like growth factor-I receptor (IGFIR) and PI3K/AKT pathways in 10 human cancer cell lines and 25 NSCLC patients with known IGFBP-3 methylation status and response to CDDP. Then, to provide a helpful tool that enables clinicians to identify patients with a potential response to CDDP, we have calculated the association between our diagnostic test and the true outcome of analyzed samples in terms of cisplatin IC50; the inhibitory concentration that kills 50% of the cell population. Our results suggest that loss of IGFBP-3 expression by promoter methylation in tumor cells treated with CDDP may activate the PI3K/AKT pathway through the specific derepression of IGFIR signaling, inducing resistance to CDDP. This study also provides a predictive test for clinical practice with an accuracy and precision of 0.84 and 0.9, respectively, (P=0.0062). We present a biomarker test that could provide clinicians with a robust tool with which to decide on the use of CDDP, improving patient clinical outcomes.
Collapse
Affiliation(s)
- M Cortés-Sempere
- Instituto de Investigaciones Biomedicas CSIC/UAM, CIBER de Enfermedades Raras CIBERER, Madrid, Spain
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Palomo C, L.Serrano, Duran S, Quiñones J, Fernandez M, Barrena I, Conde E, Quejido A, de Salazar JMG, Sedano L. Quality assurance of Li-Pb eutectic alloy as nuclear material qualification of commercial and R&D material ingots. Fusion Engineering and Design 2011. [DOI: 10.1016/j.fusengdes.2011.03.098] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
37
|
Barrado A, Fernández M, Conde E, Quejido A, Quiñones J, Sedano L. Preliminary studies of in-cell electrophoresis as 6Li enrichment technique. Fusion Engineering and Design 2011. [DOI: 10.1016/j.fusengdes.2010.11.028] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
38
|
Arana A, Wentworth C, Fernández-Vidaurre C, Schlienger R, Conde E, Arellano F. Incidence of cancer in the context of atopic dermatitis: reply from authors. Br J Dermatol 2011. [DOI: 10.1111/j.1365-2133.2011.10228.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
39
|
Arana A, Wentworth CE, Fernández-Vidaurre C, Schlienger RG, Conde E, Arellano FM. Incidence of cancer in the general population and in patients with or without atopic dermatitis in the U.K. Br J Dermatol 2011; 163:1036-43. [PMID: 20545690 DOI: 10.1111/j.1365-2133.2010.09887.x] [Citation(s) in RCA: 62] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
BACKGROUND Atopic dermatitis (AD) affects approximately 20% of children and 1-3% of adults in developed countries. OBJECTIVE To study the incidence of cancer in patients with AD in the U.K. general population. METHODS We conducted a follow-up study in the U.K. using The Health Improvement Network (THIN) database. We calculated the incidence rate (IR) of the first occurrence of overall cancer, lymphoma, melanoma and nonmelanoma skin cancer (NMSC) in the general population, in patients with AD and in individuals without AD. In addition we calculated the IR ratio (IRR) of overall cancer and subtypes of cancer in patients with AD vs. those without. RESULTS The study population included 4,518,131 patients [2,336,230 (51·7%) female]. There were 129,972 subjects [68,688 (52·8%) female] with a diagnosis of cancer (excluding NMSC). The IR (per 10,000 person-years) of cancer (excluding NMSC) was 42·41 [95% confidence interval (CI) 42·18-42·64]; of lymphoma 1·70 (95% CI 1·65-1·74); of skin melanoma 1·71 (95% CI 1·67-1·76) and of NMSC 11·76 (95% CI 11·64-11·88). The age- and sex-adjusted IRR for cancer (excluding NMSC) was 1·49 (95% CI 1·39-1·61); for lymphoma 2·21 (95% CI 1·65-2·98); for melanoma 1·74 (95% CI 1·25-2·41); and for NMSC 1·46 (95% CI 1·27-1·69). CONCLUSIONS Our results indicate an increased incidence of cancer overall as well as of specific cancer subtypes, including lymphoma, in patients with AD. Further studies are needed to disentangle the effects of treatment for AD from AD itself.
Collapse
Affiliation(s)
- A Arana
- Risk Management Resources, Pharmacovigilance Services SL, 50001 Zaragoza, Spain.
| | | | | | | | | | | |
Collapse
|
40
|
Calvo-Plaza I, Suarez-Gauthier A, Ugidos L, Lopez-Rios F, Perez-Rodriguez F, Garcia-Garcia E, Conde E, Angulo B, Hidalgo M, Estevez L. Abstract P1-15-06: Incidence of HER2 Positive Quantified by FISH in Ductal Breast Carcinoma In Situ. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p1-15-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose: The Her2/neu gene is amplified and/or its protein is overexpressed in 15-25% of invasive breast cancer, but in Ductal Carcinoma In Situ (DCIS) this expression is highly increased (60-80%). We review our rate of DCIS with Her2 amplified in a prospective series of women with new diagnosis of DCIS. Methods: Patients with new diagnosis of DCIS by biopsy were studied. The status of Her2 was evaluated by fluorescence in situ hybridization (Vysis path vision HER-2 DNA probe kit) and was considered amplified if the ratio HER2/CEP17 was >2.0. The status of estrogen and progesterone receptors were analyzed by inmunohistochemistry (IHQ). Data evaluating architectural pattern and histological grade were also collected. Results: Data from 53 patients with DCIS were included (two patients with combined invasive ductal carcinoma detected at time of surgery and 51 cases of pure DCIS). HER2 was amplified in 20 patients (37%), with HER2/CEP17 ratios between 2.16 to 14.00. A total of 29 patients had grade III DCIS, and of those 18 (62%) had Her2 amplified. 17 patients (32%) were estrogen and progesterone receptors negative (10 with Her2 amplified). We have not observed any correlation about architectural pattern (comedo, cribriform, micropapillary, solid/necrotic) and amplification of Her2. Conclusion: In our series of DCIS patients the Her2 amplification was less commonly found compared to prior studies (37% vs >60%). Most of DCIS were grade 3 (90%) and no relation was found among the architectural pattern and amplification of Her2.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P1-15-06.
Collapse
Affiliation(s)
- I Calvo-Plaza
- Centro Integral Oncologico Clara Campal, Madrid, Spain
| | | | - L Ugidos
- Centro Integral Oncologico Clara Campal, Madrid, Spain
| | - F Lopez-Rios
- Centro Integral Oncologico Clara Campal, Madrid, Spain
| | | | | | - E Conde
- Centro Integral Oncologico Clara Campal, Madrid, Spain
| | - B Angulo
- Centro Integral Oncologico Clara Campal, Madrid, Spain
| | - M Hidalgo
- Centro Integral Oncologico Clara Campal, Madrid, Spain
| | - L. Estevez
- Centro Integral Oncologico Clara Campal, Madrid, Spain
| |
Collapse
|
41
|
López-Encuentra A, López-Ríos F, Conde E, García-Luján R, Suárez-Gauthier A, Mañes N, Renedo G, Duque-Medina JL, García-Lagarto E, Rami-Porta R, González-Pont G, Astudillo-Pombo J, Maté-Sanz JL, Freixinet J, Romero-Saavedra T, Sánchez-Céspedes M, Gómez de la Camara A. Composite anatomical-clinical-molecular prognostic model in non-small cell lung cancer. Eur Respir J 2010; 37:136-42. [PMID: 20817702 DOI: 10.1183/09031936.00028610] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
The objective of the present study was to elaborate a survival model that integrates anatomic factors, according to the 2010 seventh edition of the tumour, node and metastasis (TNM) staging system, with clinical and molecular factors. Pathologic TNM descriptors (group A), clinical variables (group B), laboratory parameters (group C) and molecular markers (tissue microarrays; group D) were collected from 512 early-stage nonsmall cell lung cancer (NSCLC) patients with complete resection. A multivariate analysis stepped supervised learning classification algorithm was used. The prognostic performance by groups was: areas under the receiver operating characteristic curve (C-index): 0.67 (group A), 0.65 (Group B), 0.57 (group C) and 0.65 (group D). Considering all variables together selected for each of the four groups (integrated group) the C-index was 0.74 (95% CI 0.70-0.79), with statistically significant differences compared with each isolated group (from p = 0.006 to p < 0.001). Variables with the greatest prognostic discrimination were the presence of another ipsilobar nodule and tumour size > 3 cm, followed by other anatomical and clinical factors, and molecular expressions of phosphorylated mammalian target of rapamycin (phospho-mTOR), Ki67cell proliferation index and phosphorylated acetyl-coenzyme A carboxylase. This study on early-stage NSCLC shows the benefit from integrating pathological TNM, clinical and molecular factors into a composite prognostic model. The model of the integrated group classified patients with significantly higher accuracy compared to the TNM 2010 staging.
Collapse
|
42
|
Pettengell R, Schmitz N, Gisselbrecht C, Caballero D, Colombat P, Conde E, Metzner B, Walewski JA, Geisler C, Goldstone A. Randomized study of rituximab in patients with relapsed or resistant follicular lymphoma prior to high-dose therapy as in vivo purging and to maintain remission following high-dose therapy. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.8005] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
43
|
Calvo-Villas JM, Martín A, Conde E, Pascual A, Heras I, Varela R, de la Rubia J, Ramirez MJ, Díez-Martín JL, Panizo C, Rodríguez-Salazar MJ, Pascual MJ, Donato EM, González-Barca E, Caballero MD. Effect of addition of rituximab to salvage chemotherapy on outcome of patients with diffuse large B-cell lymphoma relapsing after an autologous stem-cell transplantation. Ann Oncol 2010; 21:1891-1897. [PMID: 20231299 DOI: 10.1093/annonc/mdq035] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND We have investigated if rituximab-based salvage regimens improve response rates and survival of patients with diffuse large B-cell lymphoma (DLBCL) relapsing after an autologous stem-cell transplantation (ASCT). PATIENTS AND METHODS We have retrospectively analyzed 82 patients with DLBCL who received salvage therapy for relapse or progression after ASCT. Patients were divided into two groups, according to whether rituximab-based salvage regimens were given (n = 42, 'R-' group) or not (n = 40, 'R+' group) after ASCT. RESULTS Patients in the R+ group had better complete remission (CR) (55% versus 21.4%, P = 0.006) and overall response (OR) (75% versus 40.4%, P = 0.001) rates, and better 3-year event-free survival (EFS) (37% versus 9%, P = 0.002) and overall survival (OS) (50% versus 20%, P = 0.005) than patients in the R- group. Patients retreated with rituximab had better CR (42.9% versus 21.4%, P = 0.032) and OR (66.7% versus 40.4%, P = 0.019) rates, and better OS (36.2% versus 20% at 3 years, P = 0.05) and EFS (36.2% versus 9% at 3 years, P = 0.05) than patients who received chemotherapy alone at relapse after ASCT. CONCLUSIONS The addition of rituximab to salvage chemotherapy improves response rates and EFS in patients with relapsed DLBCL after ASCT. These patients may benefit from rituximab retreatment, although larger prospective studies are needed to confirm these results.
Collapse
Affiliation(s)
- J M Calvo-Villas
- Department of Hematology, Hospital Doctor José Molina Orosa, Arrecife de Lanzarote.
| | - A Martín
- Department of Hematology, Complejo Asistencial de Zamora, Zamora
| | - E Conde
- Department of Hematology, Hospital Marqués de Valdecilla, Santander
| | - A Pascual
- Department of Hematology, Hospital Clinico Universitario San Carlos, Madrid
| | - I Heras
- Department of Hematology, Hospital Morales Meseguer, Murcia
| | - R Varela
- Department of Hematology, Hospital Juan Canalejo, La Coruña
| | | | - M J Ramirez
- Department of Hematology, Hospital General de Jerez, Jerez de la Frontera
| | | | - C Panizo
- Department of Hematology, Clínica Universitaria de Navarra, Pamplona
| | | | - M J Pascual
- Department of Hematology, Hospital Carlos Haya, Malaga
| | - E M Donato
- Department of Hematology, Hospital General de Castellón, Castellón
| | - E González-Barca
- Department of Hematology, Institut Catalá d'Oncología-Hospital Duran i Reynals, L'Hospitalet de Llobregat
| | - M D Caballero
- Department of Hematology, Hospital Clínico Universitario, Salamanca, Spain
| | | |
Collapse
|
44
|
Gomez-Martin C, Garcia-Garcia E, Suarez-Gauthier A, Conde E, Lopez-Rios F. 6652 Comparison of fluorescence in situ hybridization and dual colour chromogenic in situ hybridization for the assessment of HER2 status on gastric cancer biopsies. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71373-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
45
|
Conde E, Cara C, Moure A, Ruiz E, Castro E, Domínguez H. Antioxidant activity of the phenolic compounds released by hydrothermal treatments of olive tree pruning. Food Chem 2009. [DOI: 10.1016/j.foodchem.2008.10.017] [Citation(s) in RCA: 97] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
46
|
Suárez-Gauthier A, García-García E, Conde E, Muñoz A, Torres M, Miró C, García-Estevez L, López-Ríos F. Comparison of fluorescence in situ hybridization and dual color chromogenic in situ hybridization for the assessment of HER2 status on core-needle breast cancer biopsies. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-3015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #3015
Background: Core-needle biopsies have been shown to be extremely useful for evaluation of prognostic and predictive markers. In breast cancer patients, this is particularly important in the setting of neoadjuvant chemotherapy. However, it is well known that immunohistochemistry can give conflictive results on small biopsies or core-needle biopsies. This study evaluates the concordance between HER2 gene amplification determined by fluorescence in situ hybridization (FISH) and a new dual color cromogenic in situ hybridization (CISH) in a series of core-needle breast biopsies.
 Material and Methods: A total of 37 invasive breast carcinomas diagnosed on core-nedle breast biopsies were selected from our files. Dual color FISH (Dako, Glostrup) and dual color CISH (Dako, Glostrup) were performed in each case. Scoring of the FISH and CISH slides was identical, counting HER2 and CEN-17 signals from 60 tumour nuclei per case. Finally, the gene to CEN-17 ratio was calculated using the cut-off value of HER2/CEN-17 ratio >2 as amplified.
 Results: All 37 specimens were analyzed successfully by CISH and FISH. A high concordance was found between FISH and CISH in the assessment of HER2 status. 12 cases were amplified and counted easily with both techniques, showing similar ratios. Polysomy was also detected with both techniques in 5 cases with no amplification.
 Discussion: Given the presumed heterogeneous expression of HER2 immunohistochemistry on core-needle biopsies, dual color CISH might be an alternative to FISH in this setting. Moreover, CISH allows for a better concurrent analysis of morphology, which is particularly important when studying small samples.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 3015.
Collapse
Affiliation(s)
- A Suárez-Gauthier
- 1 Laboratorio de Dianas Terapéuticas, Centro Integral Oncológico Clara Campal, Hospital Madrid-Norte Sanchinarro, Madrid, Spain
| | - E García-García
- 1 Laboratorio de Dianas Terapéuticas, Centro Integral Oncológico Clara Campal, Hospital Madrid-Norte Sanchinarro, Madrid, Spain
| | - E Conde
- 1 Laboratorio de Dianas Terapéuticas, Centro Integral Oncológico Clara Campal, Hospital Madrid-Norte Sanchinarro, Madrid, Spain
| | - A Muñoz
- 1 Laboratorio de Dianas Terapéuticas, Centro Integral Oncológico Clara Campal, Hospital Madrid-Norte Sanchinarro, Madrid, Spain
| | - M Torres
- 2 Breast Unit, Centro Integral Oncológico Clara Campal, Hospital Madrid-Norte Sanchinarro, Madrid, Spain
| | - C Miró
- 2 Breast Unit, Centro Integral Oncológico Clara Campal, Hospital Madrid-Norte Sanchinarro, Madrid, Spain
| | - L García-Estevez
- 2 Breast Unit, Centro Integral Oncológico Clara Campal, Hospital Madrid-Norte Sanchinarro, Madrid, Spain
| | - F López-Ríos
- 1 Laboratorio de Dianas Terapéuticas, Centro Integral Oncológico Clara Campal, Hospital Madrid-Norte Sanchinarro, Madrid, Spain
| |
Collapse
|
47
|
Martin A, Conde E, Arnan M, Canales MA, Deben G, Sancho JM, Andreu R, Salar A, Garcia-Sanchez P, Vazquez L, Nistal S, Requena MJ, Donato EM, Gonzalez JA, Leon A, Ruiz C, Grande C, Gonzalez-Barca E, Caballero MD. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. Haematologica 2008; 93:1829-36. [DOI: 10.3324/haematol.13440] [Citation(s) in RCA: 136] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
|
48
|
Iriondo A, Hermosa V, Richard C, Conde E, Bello C, Garijo J, Baro J, Zubizarreta Z. GRAFT REJECTION FOLLOWING T LYMPHOCYTE DEPLETED BONE MARROW TRANSPLANTATION WITH TWO DIFFERENT TBI REGIMENS. Br J Haematol 2008. [DOI: 10.1111/j.1365-2141.1987.00245.x-i1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
49
|
Angulo B, Suarez-Gauthier A, Lopez-Rios F, Medina PP, Conde E, Tang M, Soler G, Lopez-Encuentra A, Cigudosa JC, Sanchez-Cespedes M. Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours and identify selective PIK3CA overexpression by gene amplification. J Pathol 2008; 214:347-56. [PMID: 17992665 DOI: 10.1002/path.2267] [Citation(s) in RCA: 76] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
The development of targeted therapies creates a need to discriminate tumours accurately by their histological and genetic characteristics. Here, we aim to identify gene expression profiles and single markers that recapitulate the pathological and genetic background of non-small cell lung cancer (NSCLC). We performed cDNA microarray analysis on a series of 69 NSCLCs, with known mutation status for important genes, and six normal lung tissues. Unsupervised cluster analysis segregated normal lungs from lung tumours and lung tumours according to their histopathology and the presence of EGFR mutations. Several transcripts were highly overexpressed (by approximately 20 times) in squamous cell carcinomas (SCCs) relative to adenocarcinomas (ACs) and confirmed by immunohistochemistry in an independent cohort of 75 lung tumours. Expression of 13 genes constituted the most prominent hallmarks of EGFR-mutant tumours, including increased levels of proline dehydrogenase (PRODH) and down-regulation of X-box binding protein 1 (XBP1). No genes were differentially expressed, with a fold change >or= 4 or <or=0.25 and a significance level of 5% false-discovery rate, in tumours carrying mutations of TP53 or KRAS. In addition, we organized gene expression data by the position of each gene in the chromosome and observed a cluster of highly expressed genes in chromosome 3q, including PIK3CA, that was characteristic of SCCs. FISH analysis demonstrated a strong statistically significant association between increased levels of PIK3CA expression in these tumours and gene amplification (p < 0.0001; t-test). In conclusion, histopathological phenotypes and, likely, the presence of EGFR mutations confer lung tumours with a marked pattern of gene expression. Moreover, our cDNA microarray analysis identified increased PIK3CA expression due to gene amplification in lung squamous cell carcinomas: this may represent a marker of sensitivity to therapy with PI3K inhibitors.
Collapse
Affiliation(s)
- B Angulo
- Lung Cancer Group, Spanish National Cancer Centre (CNIO), 28029 Madrid, Spain
| | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Montoto S, Canals C, Rohatiner AZS, Taghipour G, Sureda A, Schmitz N, Gisselbrecht C, Fouillard L, Milpied N, Haioun C, Slavin S, Conde E, Fruchart C, Ferrant A, Leblond V, Tilly H, Lister TA, Goldstone AH. Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. Leukemia 2007; 21:2324-31. [PMID: 17637813 DOI: 10.1038/sj.leu.2404850] [Citation(s) in RCA: 124] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
To evaluate the outcome of a large series of patients who received high-dose treatment (HDT) for follicular lymphoma (FL), 693 patients undergoing HDT (total-body irradiation (TBI)-containing regimen: 58%; autologous bone marrow (BM)/peripheral blood progenitor cells (PBPCs): 378/285 patients) were included in the study. A total of 375 patients (54%) developed recurrent lymphoma, 10-year progression-free survival (PFS) being 31%. On multivariate analysis, younger age (P=0.003) and HDT in first complete remission (CR1) (P<0.001) correlated with longer PFS. With a median follow-up of 10.3 years, 330 patients died. Ten-year overall survival (OS) from HDT was 52%. Shorter OS was associated on multivariate analysis with older age (P<0.001), chemoresistant disease (P<0.001), BM+PBPC as source of stem cells (P=0.007) and TBI-containing regimens (P=0.004). Thirty-nine patients developed secondary myelodysplastic syndrome/acute myeloid leukaemia (MDS/AML), in 34 cases having received TBI as the conditioning regimen. The 5-year non-relapse mortality (NRM) was 9%. On multivariate analysis, older age (P<0.001), refractory disease (P<0.001) and TBI (P=0.04) were associated with a higher NRM. This long follow-up study shows a plateau in the PFS curve, suggesting that a selected group of patients might be cured with HDT. On the downside, TBI-containing regimens are associated with a negative impact on survival.
Collapse
Affiliation(s)
- S Montoto
- Cancer Research UK Medical Oncology Unit, Institute of Cancer, Centre for Medical Oncology, Barts and the London, Queen Mary's School of Medicine and Dentistry, London, UK.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|